Press Center
Jan 20, 2026
Press release
Corporate and finance,Partnerships,Science & technology

Novavax Announces Entering into a License Agreement with Pfizer

Jan 7, 2026
Corporate and finance

Novavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Nov 12, 2025
Corporate and finance

Novavax to Participate in Jefferies London Healthcare Conference

Nov 6, 2025
Corporate and finance

Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights

Perspectives & Insights

Explore our blog for valuable insights and inspiring stories from our team as we fulfill our vision to spark transformation in global health.

R&D Reflections from the Global Vaccine Stage Image Collage
Winter 2025
Research & Development
By Ruxandra Draghia-Akli, MD, PhD, EVP, Head of Research & Development

In the News

See what others are saying about Novavax.

PharmaVoice

Has Novavax cracked the code for survival in the vaccine arena?

Pink Sheet

The vaccine maker’s three-year transformation from commercial company to lean platform player is firmly on track.

Endpoints

Every FDA drug approval in 2025

Becker's Hospital Review

The 20 most influential drug approvals of 2025

MedCity News

Novavax Sees Sanofi Vaccine Pact as Model for Future Deals, Some Going Beyond Infectious Disease

Contagion Live

Novavax COVID-19 Vaccine Linked to Fewer Side Effects in Health Care Workers and First Responders

Note: This section features articles written by external media outlets and journalists.

Media
contact

Phone
(844) 264-8571
Email
media@novavax.com

Images, videos and files for media use

Resources for members of the press.

About Novavax

We tackle some of the world's most significant health challenges by leveraging our scientific expertise in vaccines and cutting-edge technology platform, including protein-based nanoparticles and Matrix-M® adjuvant.